Phase II Trial of Allovectin-7® for Metastatic Melanoma
NCT ID: NCT00044356
Last Updated: 2011-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
133 participants
INTERVENTIONAL
2001-02-28
2004-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00003646
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00003647
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
NCT00470015
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
NCT00010309
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
NCT00099970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allovectin-7®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* You have been diagnosed with Stage III or Stage IV melanoma
* Your cancer has returned after a prior treatment (e.g. radiation or chemotherapy) or you refused therapy with standard treatment
* You are able to carry out your normal daily activities
* Your melanoma has not spread to your brain
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vical Incorporated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Arizona Cancer Center
Tucson, Arizona, United States
University of Arkansas Cancer Research Center
Little Rock, Arkansas, United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado Cancer Center
Denver, Colorado, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Louisiana State University Medical Center
New Orleans, Louisiana, United States
Hematology Oncology Associates of Baltimore
Baltimore, Maryland, United States
North Memorial Health Care
Robbinsdale, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
The Melanoma Center of Saint Louis
St Louis, Missouri, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Beth Israel Medical Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
MD Anderson Cancer Center
Houston, Texas, United States
Cancer Care Alliance
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VCL-1005-208
Identifier Type: -
Identifier Source: org_study_id
NCT00028444
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.